van der Zijden CJ, Eyck BM, van der Gaast A, et al. ChemoTherapy aNd chemoradioTherapy for adenocarcinoma of the OESophagus and esophagogastric junction with oligometastases: protocol of the TNT-OES-1 trial. Contemp Clin Trials Commun 2022;28:100934.

• PubMed
van der Zijden CJ, Eyck BM, van der Gaast A, ChemoTherapy aNd chemoradioTherapy for adenocarcinoma of the OESophagus and esophagogastric junction with oligometastases: protocol of the TNT-OES-1 trial. Contemp Clin Trials Commun 2022;28:100934.)| false
• Search Google Scholar
• Export Citation

van Hagen P, Hulshof MCCM, van Lanschot JJB, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012;366:2074–2084.

• PubMed
van Hagen P, Hulshof MCCM, van Lanschot JJB, Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012;366:2074–2084.)| false
• Search Google Scholar
• Export Citation

Al-Batran SE, Homann N, Pauligk C, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet 2019;393:1948–1957.

• PubMed
Al-Batran SE, Homann N, Pauligk C, Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet 2019;393:1948–1957.)| false
• Search Google Scholar
• Export Citation

Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 2021;384:1191–1203.

• PubMed
Kelly RJ, Ajani JA, Kuzdzal J, Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 2021;384:1191–1203.)| false
• Search Google Scholar
• Export Citation

Hoeppner J, Brunner T, Schmoor C, et al. Perioperative chemotherapy or preoperative chemoradiotherapy in esophageal cancer. N Engl J Med 2025;392:323–335.

• PubMed
Hoeppner J, Brunner T, Schmoor C, Perioperative chemotherapy or preoperative chemoradiotherapy in esophageal cancer. N Engl J Med 2025;392:323–335.)| false
• Search Google Scholar
• Export Citation

Allum WH, Stenning SP, Bancewicz J, et al. Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol 2009;27:5062–5067.

• PubMed
Allum WH, Stenning SP, Bancewicz J, Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol 2009;27:5062–5067.)| false
• Search Google Scholar
• Export Citation

Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006;355:11–20.

• PubMed
Cunningham D, Allum WH, Stenning SP, Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006;355:11–20.)| false
• Search Google Scholar
• Export Citation

Shah MA, Kennedy EB, Catenacci DV, et al. Treatment of locally advanced esophageal carcinoma: ASCO guideline. J Clin Oncol 2020;38:2677–2694.

• PubMed
Shah MA, Kennedy EB, Catenacci DV, Treatment of locally advanced esophageal carcinoma: ASCO guideline. J Clin Oncol 2020;38:2677–2694.)| false
• Search Google Scholar
• Export Citation

Obermannová R, Alsina M, Cervantes A, et al. Oesophageal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol 2022;33:992–1004.

• PubMed
Obermannová R, Alsina M, Cervantes A, Oesophageal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol 2022;33:992–1004.)| false
• Search Google Scholar
• Export Citation

Ajani JA, D’Amico TA, Bentrem DJ, et al. NCCN Clinical Practice Guidelines in Oncology: Esophageal and Esophagogastric Junction Cancers. Version 2.2023. Accessed March 24, 2024. To view the most recent version, visit https://www.nccn.org

• PubMed
Ajani JA, D’Amico TA, Bentrem DJ, NCCN Clinical Practice Guidelines in Oncology: Esophageal and Esophagogastric Junction Cancers. Version 2.2023. Accessed March 24, 2024. To view the most recent version, visit https://www.nccn.org)| false
• Search Google Scholar
• Export Citation

Reynolds JV, Preston SR, O’Neill B, et al. Trimodality therapy versus perioperative chemotherapy in the management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction (Neo-AEGIS): an open-label, randomised, phase 3 trial. Lancet Gastroenterol Hepatol 2023;8:1015–1027.

• PubMed
Reynolds JV, Preston SR, O’Neill B, Trimodality therapy versus perioperative chemotherapy in the management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction (Neo-AEGIS): an open-label, randomised, phase 3 trial. Lancet Gastroenterol Hepatol 2023;8:1015–1027.)| false
• Search Google Scholar
• Export Citation

Schulz C, Kullmann F, Kunzmann V, et al. NeoFLOT: multicenter phase II study of perioperative chemotherapy in resectable adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma—very good response predominantly in patients with intestinal type tumors. Int J Cancer 2015;137:678–685.

• PubMed
Schulz C, Kullmann F, Kunzmann V, NeoFLOT: multicenter phase II study of perioperative chemotherapy in resectable adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma—very good response predominantly in patients with intestinal type tumors. Int J Cancer 2015;137:678–685.)| false
• Search Google Scholar
• Export Citation

Wo JY, Clark JW, Eyler CE, et al. Results and molecular correlates from a pilot study of neoadjuvant induction FOLFIRINOX followed by chemoradiation and surgery for gastroesophageal adenocarcinomas. Clin Cancer Res 2021;27:6343–6353.

• PubMed
Wo JY, Clark JW, Eyler CE, Results and molecular correlates from a pilot study of neoadjuvant induction FOLFIRINOX followed by chemoradiation and surgery for gastroesophageal adenocarcinomas. Clin Cancer Res 2021;27:6343–6353.)| false
• Search Google Scholar
• Export Citation

Goodman KA, Ou FS, Hall NC, et al. Randomized phase II study of PET response–adapted combined modality therapy for esophageal cancer: mature results of the CALGB 80803 (Alliance) trial. J Clin Oncol 2021;39:2803–2815.

• PubMed
Goodman KA, Ou FS, Hall NC, Randomized phase II study of PET response–adapted combined modality therapy for esophageal cancer: mature results of the CALGB 80803 (Alliance) trial. J Clin Oncol 2021;39:2803–2815.)| false
• Search Google Scholar
• Export Citation

Leong T, Smithers BM, Michael M, et al. Preoperative chemoradiotherapy for resectable gastric cancer. N Engl J Med 2024;391:1810–1821.

• PubMed
Leong T, Smithers BM, Michael M, Preoperative chemoradiotherapy for resectable gastric cancer. N Engl J Med 2024;391:1810–1821.)| false
• Search Google Scholar
• Export Citation

Slagter AE, Jansen EPM, van Laarhoven HWM, et al. CRITICS-II: a multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery versus neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery in resectable gastric cancer. BMC Cancer 2018;18:877.

• PubMed
Slagter AE, Jansen EPM, van Laarhoven HWM, CRITICS-II: a multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery versus neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery in resectable gastric cancer. BMC Cancer 2018;18:877.)| false
• Search Google Scholar
• Export Citation

Lorenzen S, Götze TO, Thuss-Patience P, et al. Perioperative atezolizumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel for resectable esophagogastric cancer: interim results from the randomized, multicenter, phase II/III DANTE/IKF-s633 trial. J Clin Oncol 2024;42:410–420.

• PubMed
Lorenzen S, Götze TO, Thuss-Patience P, Perioperative atezolizumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel for resectable esophagogastric cancer: interim results from the randomized, multicenter, phase II/III DANTE/IKF-s633 trial. J Clin Oncol 2024;42:410–420.)| false
• Search Google Scholar
• Export Citation

Liu X, Jin J, Cai H, et al. Study protocol of a randomized phase III trial of comparing preoperative chemoradiation with preoperative chemotherapy in patients with locally advanced gastric cancer or esophagogastric junction adenocarcinoma: PREACT. BMC Cancer 2019;19:606.

• PubMed
Liu X, Jin J, Cai H, Study protocol of a randomized phase III trial of comparing preoperative chemoradiation with preoperative chemotherapy in patients with locally advanced gastric cancer or esophagogastric junction adenocarcinoma: PREACT. BMC Cancer 2019;19:606.)| false
• Search Google Scholar
• Export Citation

Janjigian YY, Ajani JA, Moehler M, et al. First-line nivolumab plus chemotherapy for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: 3-year follow-up of the phase III CheckMate 649 trial. J Clin Oncol 2024;42:2012–2020.

• PubMed
Janjigian YY, Ajani JA, Moehler M, First-line nivolumab plus chemotherapy for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: 3-year follow-up of the phase III CheckMate 649 trial. J Clin Oncol 2024;42:2012–2020.)| false
• Search Google Scholar
• Export Citation

Sun JM, Shen L, Shah MA, et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet 2021;398:759–771.

• PubMed
Sun JM, Shen L, Shah MA, Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet 2021;398:759–771.)| false
• Search Google Scholar
• Export Citation

Blum Murphy M, Xiao L, Patel VR, et al. Pathological complete response in patients with esophageal cancer after the trimodality approach: the association with baseline variables and survival—the University of Texas MD Anderson Cancer Center experience. Cancer 2017;123:4106–4113.

• PubMed
Blum Murphy M, Xiao L, Patel VR, Pathological complete response in patients with esophageal cancer after the trimodality approach: the association with baseline variables and survival—the University of Texas MD Anderson Cancer Center experience. Cancer 2017;123:4106–4113.)| false
• Search Google Scholar
• Export Citation

Eads JR, Graham N, Gibson MK, et al. A phase II/III study of peri-operative nivolumab (nivo) and ipilimumab (ipi) in patients (pts) with locoregional esophageal (E) and gastroesophageal junction (GEJ) adenocarcinoma: results of the neoadjuvant pathologic complete response (pCR) rate (ECOG-ACRIN EA2174). J Clin Oncol 2024;42(Suppl 16):Abstract 4000.

• PubMed
Eads JR, Graham N, Gibson MK, A phase II/III study of peri-operative nivolumab (nivo) and ipilimumab (ipi) in patients (pts) with locoregional esophageal (E) and gastroesophageal junction (GEJ) adenocarcinoma: results of the neoadjuvant pathologic complete response (pCR) rate (ECOG-ACRIN EA2174). J Clin Oncol 2024;42(Suppl 16):Abstract 4000.)| false
• Search Google Scholar
• Export Citation

Shitara K, Rha SY, Wyrwicz LS, et al. Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study. Lancet Oncol 2024;25:212–224.

• PubMed
Shitara K, Rha SY, Wyrwicz LS, Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study. Lancet Oncol 2024;25:212–224.)| false
• Search Google Scholar
• Export Citation

Oh DY, Janjigian YY, Al-Batran SE, et al. Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): interim results of the global, phase III MATTERHORN study. Ann Oncol 2023;34:S1520–1521.

• PubMed
Oh DY, Janjigian YY, Al-Batran SE, Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): interim results of the global, phase III MATTERHORN study. Ann Oncol 2023;34:S1520–1521.)| false
• Search Google Scholar
• Export Citation

Smyth EC, Wotherspoon A, Peckitt C, et al. Mismatch repair deficiency, microsatellite instability, and survival: an exploratory analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) trial. JAMA Oncol 2017;3:1197–1203.

• PubMed
Smyth EC, Wotherspoon A, Peckitt C, Mismatch repair deficiency, microsatellite instability, and survival: an exploratory analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) trial. JAMA Oncol 2017;3:1197–1203.)| false
• Search Google Scholar
• Export Citation

Choi YY, Kim H, Shin SJ, et al. Microsatellite instability and programmed cell death-ligand 1 expression in stage II/III gastric cancer: post hoc analysis of the CLASSIC randomized controlled study. Ann Surg 2019;270:309–316.

• PubMed
Choi YY, Kim H, Shin SJ, Microsatellite instability and programmed cell death-ligand 1 expression in stage II/III gastric cancer: post hoc analysis of the CLASSIC randomized controlled study. Ann Surg 2019;270:309–316.)| false
• Search Google Scholar
• Export Citation

Strickland MR, Lander EM, Gibson MK, et al. Gastroesophageal adenocarcinomas with defective mismatch repair: current knowledge and clinical management. J Natl Compr Canc Netw 2024;22:e237103.

• PubMed
Strickland MR, Lander EM, Gibson MK, Gastroesophageal adenocarcinomas with defective mismatch repair: current knowledge and clinical management. J Natl Compr Canc Netw 2024;22:e237103.)| false
• Search Google Scholar
• Export Citation

André T, Tougeron D, Piessen G, et al. Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in localized deficient mismatch repair/microsatellite instability–high gastric or esophagogastric junction adenocarcinoma: the GERCOR NEONIPIGA phase II study. J Clin Oncol 2023;41:255–265.

• PubMed
André T, Tougeron D, Piessen G, Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in localized deficient mismatch repair/microsatellite instability–high gastric or esophagogastric junction adenocarcinoma: the GERCOR NEONIPIGA phase II study. J Clin Oncol 2023;41:255–265.)| false
• Search Google Scholar
• Export Citation

Ludford K, Ho WJ, Thomas JV, et al. Neoadjuvant pembrolizumab in localized microsatellite instability high/deficient mismatch repair solid tumors. J Clin Oncol 2023;41:2181–2190.

• PubMed
Ludford K, Ho WJ, Thomas JV, Neoadjuvant pembrolizumab in localized microsatellite instability high/deficient mismatch repair solid tumors. J Clin Oncol 2023;41:2181–2190.)| false
• Search Google Scholar
• Export Citation

Pietrantonio F, Raimondi A, Lonardi S, et al. INFINITY: a multicentre, single-arm, multi-cohort, phase II trial of tremelimumab and durvalumab as neoadjuvant treatment of patients with microsatellite instability-high (MSI) resectable gastric or gastroesophageal junction adenocarcinoma (GAC/GEJAC). J Clin Oncol 2023;41(Suppl 4):Abstract 358.

• PubMed
Pietrantonio F, Raimondi A, Lonardi S, INFINITY: a multicentre, single-arm, multi-cohort, phase II trial of tremelimumab and durvalumab as neoadjuvant treatment of patients with microsatellite instability-high (MSI) resectable gastric or gastroesophageal junction adenocarcinoma (GAC/GEJAC). J Clin Oncol 2023;41(Suppl 4):Abstract 358.)| false
• Search Google Scholar
• Export Citation

Bang YJ, Van Cutsem E, Fuchs CS, et al. KEYNOTE-585: phase III study of perioperative chemotherapy with or without pembrolizumab for gastric cancer. Future Oncol 2019;15:943–952.

• PubMed
Bang YJ, Van Cutsem E, Fuchs CS, KEYNOTE-585: phase III study of perioperative chemotherapy with or without pembrolizumab for gastric cancer. Future Oncol 2019;15:943–952.)| false
• Search Google Scholar
• Export Citation

Lorenzen S, Biederstädt A, Ronellenfitsch U, et al. RACE-trial: neoadjuvant radiochemotherapy versus chemotherapy for patients with locally advanced, potentially resectable adenocarcinoma of the gastroesophageal junction – a randomized phase III joint study of the AIO, ARO and DGAV. BMC Cancer 2020;20:886.

• PubMed
Lorenzen S, Biederstädt A, Ronellenfitsch U, RACE-trial: neoadjuvant radiochemotherapy versus chemotherapy for patients with locally advanced, potentially resectable adenocarcinoma of the gastroesophageal junction – a randomized phase III joint study of the AIO, ARO and DGAV. BMC Cancer 2020;20:886.)| false
• Search Google Scholar
• Export Citation

Janjigian YY, Kawazoe A, Bai Y, et al. Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial. Lancet 2023;402:2197–2208.

• PubMed
Janjigian YY, Kawazoe A, Bai Y, Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial. Lancet 2023;402:2197–2208.)| false
• Search Google Scholar
• Export Citation

Safran HP, Winter K, Ilson DH, et al. Trastuzumab with trimodality treatment for oesophageal adenocarcinoma with HER2 overexpression (NRG Oncology/RTOG 1010): a multicentre, randomised, phase 3 trial. Lancet Oncol 2022;23:259–269.

• PubMed
Safran HP, Winter K, Ilson DH, Trastuzumab with trimodality treatment for oesophageal adenocarcinoma with HER2 overexpression (NRG Oncology/RTOG 1010): a multicentre, randomised, phase 3 trial. Lancet Oncol 2022;23:259–269.)| false
• Search Google Scholar
• Export Citation

Swain SM, Baselga J, Kim SB, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med 2015;372:724–734.

• PubMed
Swain SM, Baselga J, Kim SB, Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med 2015;372:724–734.)| false
• Search Google Scholar
• Export Citation

Ruhstaller T, Thuss-Patience P, Hayoz S, et al. Neoadjuvant chemotherapy followed by chemoradiation and surgery with and without cetuximab in patients with resectable esophageal cancer: a randomized, open-label, phase III trial (SAKK 75/08). Ann Oncol 2018;29:1386–1393.

• PubMed
Ruhstaller T, Thuss-Patience P, Hayoz S, Neoadjuvant chemotherapy followed by chemoradiation and surgery with and without cetuximab in patients with resectable esophageal cancer: a randomized, open-label, phase III trial (SAKK 75/08). Ann Oncol 2018;29:1386–1393.)| false
• Search Google Scholar
• Export Citation

Suntharalingam M, Winter K, Ilson D, et al. Effect of the addition of cetuximab to paclitaxel, cisplatin, and radiation therapy for patients with esophageal cancer: the NRG Oncology RTOG 0436 phase 3 randomized clinical trial. JAMA Oncol 2017;3:1520–1528.

• PubMed
Suntharalingam M, Winter K, Ilson D, Effect of the addition of cetuximab to paclitaxel, cisplatin, and radiation therapy for patients with esophageal cancer: the NRG Oncology RTOG 0436 phase 3 randomized clinical trial. JAMA Oncol 2017;3:1520–1528.)| false
• Search Google Scholar
• Export Citation

Cunningham D, Stenning SP, Smyth EC, et al. Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2-3 trial. Lancet Oncol 2017;18:357–370.

• PubMed
Cunningham D, Stenning SP, Smyth EC, Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2-3 trial. Lancet Oncol 2017;18:357–370.)| false
• Search Google Scholar
• Export Citation

Shah MA, Bennouna J, Doi T, et al. KEYNOTE-975 study design: a phase III study of definitive chemoradiotherapy plus pembrolizumab in patients with esophageal carcinoma. Future Oncol 2021;17:1143–1153.

• PubMed
Shah MA, Bennouna J, Doi T, KEYNOTE-975 study design: a phase III study of definitive chemoradiotherapy plus pembrolizumab in patients with esophageal carcinoma. Future Oncol 2021;17:1143–1153.)| false
• Search Google Scholar
• Export Citation

Hofheinz RD, Haag GM, Ettrich TJ, et al. Perioperative trastuzumab and pertuzumab in combination with FLOT versus FLOT alone for HER2-positive resectable esophagogastric adenocarcinoma: final results of the PETRARCA multicenter randomized phase II trial of the AIO. J Clin Oncol 2020;38(Suppl 15):Abstract 4502.

• PubMed
Hofheinz RD, Haag GM, Ettrich TJ, Perioperative trastuzumab and pertuzumab in combination with FLOT versus FLOT alone for HER2-positive resectable esophagogastric adenocarcinoma: final results of the PETRARCA multicenter randomized phase II trial of the AIO. J Clin Oncol 2020;38(Suppl 15):Abstract 4502.)| false
• Search Google Scholar
• Export Citation

Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010;376:687–697.

• PubMed
Bang YJ, Van Cutsem E, Feyereislova A, Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010;376:687–697.)| false
• Search Google Scholar
• Export Citation

Okereke IC, Westra J, Tyler D, et al. Disparities in esophageal cancer care based on race: a National Cancer Database analysis. Dis Esophagus 2022;35:doab083.

• PubMed
Okereke IC, Westra J, Tyler D, Disparities in esophageal cancer care based on race: a National Cancer Database analysis. Dis Esophagus 2022;35:doab083.)| false
• Search Google Scholar
• Export Citation

Smyth EC, Fassan M, Cunningham D, et al. Effect of pathologic tumor response and nodal status on survival in the Medical Research Council Adjuvant Gastric Infusional Chemotherapy trial. J Clin Oncol 2016;34:2721–2727.

• PubMed
Smyth EC, Fassan M, Cunningham D, Effect of pathologic tumor response and nodal status on survival in the Medical Research Council Adjuvant Gastric Infusional Chemotherapy trial. J Clin Oncol 2016;34:2721–2727.)| false
• Search Google Scholar
• Export Citation

Kurnit KC, Dumbrava EEI, Litzenburger B, et al. Precision oncology decision support: current approaches and strategies for the future. Clin Cancer Res 2018;24:2719–2731.

• PubMed
Kurnit KC, Dumbrava EEI, Litzenburger B, Precision oncology decision support: current approaches and strategies for the future. Clin Cancer Res 2018;24:2719–2731.)| false
• Search Google Scholar
• Export Citation

Ott K, Weber WA, Lordick F, et al. Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. J Clin Oncol 2006;24:4692–4698.

• PubMed
Ott K, Weber WA, Lordick F, Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. J Clin Oncol 2006;24:4692–4698.)| false
• Search Google Scholar
• Export Citation

Ilson DH, Minsky BD, Ku GY, et al. Phase 2 trial of induction and concurrent chemoradiotherapy with weekly irinotecan and cisplatin followed by surgery for esophageal cancer. Cancer 2012;118:2820–2827.

• PubMed
Ilson DH, Minsky BD, Ku GY, Phase 2 trial of induction and concurrent chemoradiotherapy with weekly irinotecan and cisplatin followed by surgery for esophageal cancer. Cancer 2012;118:2820–2827.)| false
• Search Google Scholar
• Export Citation

Weber WA, Ott K, Becker K, et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 2001;19:3058–3065.

• PubMed
Weber WA, Ott K, Becker K, Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 2001;19:3058–3065.)| false
• Search Google Scholar
• Export Citation

Zum Büschenfelde CM, Herrmann K, Schuster T, et al. (18)F-FDG PET-guided salvage neoadjuvant radiochemotherapy of adenocarcinoma of the esophagogastric junction: the MUNICON II trial. J Nucl Med 2011;52:1189–1196.

• PubMed
Zum Büschenfelde CM, Herrmann K, Schuster T, (18)F-FDG PET-guided salvage neoadjuvant radiochemotherapy of adenocarcinoma of the esophagogastric junction: the MUNICON II trial. J Nucl Med 2011;52:1189–1196.)| false
• Search Google Scholar
• Export Citation

Azad TD, Chaudhuri AA, Fang P, et al. Circulating tumor DNA analysis for detection of minimal residual disease after chemoradiotherapy for localized esophageal cancer. Gastroenterology 2020;158:494–505.e6.

• PubMed
Azad TD, Chaudhuri AA, Fang P, Circulating tumor DNA analysis for detection of minimal residual disease after chemoradiotherapy for localized esophageal cancer. Gastroenterology 2020;158:494–505.e6.)| false
• Search Google Scholar
• Export Citation

Ococks E, Frankell AM, Masque Soler N, et al. Longitudinal tracking of 97 esophageal adenocarcinomas using liquid biopsy sampling. Ann Oncol 2021;32:522–532.

• PubMed
Ococks E, Frankell AM, Masque Soler N, Longitudinal tracking of 97 esophageal adenocarcinomas using liquid biopsy sampling. Ann Oncol 2021;32:522–532.)| false
• Search Google Scholar
• Export Citation

Huffman BM, Aushev VN, Budde GL, et al. Analysis of circulating tumor DNA to predict risk of recurrence in patients with esophageal and gastric cancers. JCO Precis Oncol 2022;6:e2200420.

• PubMed
Huffman BM, Aushev VN, Budde GL, Analysis of circulating tumor DNA to predict risk of recurrence in patients with esophageal and gastric cancers. JCO Precis Oncol 2022;6:e2200420.)| false
• Search Google Scholar
• Export Citation

Zaanan A, Didelot A, Broudin C, et al. Longitudinal circulating tumor DNA (ctDNA) analysis during treatment (Tx) of locally advanced resectable (LAR) gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (ADENOCA): the PLAGAST prospective biomarker study. J Clin Oncol 2024;42(Suppl 16):Abstract 4028.

• PubMed
Zaanan A, Didelot A, Broudin C, Longitudinal circulating tumor DNA (ctDNA) analysis during treatment (Tx) of locally advanced resectable (LAR) gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (ADENOCA): the PLAGAST prospective biomarker study. J Clin Oncol 2024;42(Suppl 16):Abstract 4028.)| false
• Search Google Scholar
• Export Citation

Leal A, van Grieken NCT, Palsgrove DN, et al. White blood cell and cell-free DNA analyses for detection of residual disease in gastric cancer. Nat Commun 2020;11:525.

• PubMed
Leal A, van Grieken NCT, Palsgrove DN, White blood cell and cell-free DNA analyses for detection of residual disease in gastric cancer. Nat Commun 2020;11:525.)| false
• Search Google Scholar
• Export Citation

Al-Batran SE, Hofheinz RD, Pauligk C, et al. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. Lancet Oncol 2016;17:1697–1708.

• PubMed
Al-Batran SE, Hofheinz RD, Pauligk C, Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. Lancet Oncol 2016;17:1697–1708.)| false
• Search Google Scholar
• Export Citation

Cats A, Jansen EPM, van Grieken NCT, et al. Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial. Lancet Oncol 2018;19:616–628.

• PubMed
Cats A, Jansen EPM, van Grieken NCT, Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial. Lancet Oncol 2018;19:616–628.)| false
• Search Google Scholar
• Export Citation

Tintelnot J, Stein A, Al-Batran SE, et al. Pembrolizumab and trastuzumab in combination with FLOT in the perioperative treatment of HER2-positive, localized esophagogastric adenocarcinoma—a phase II trial of the AIO study group (AIO STO 0321). Front Oncol 2023;13:1272175.

• PubMed
Tintelnot J, Stein A, Al-Batran SE, Pembrolizumab and trastuzumab in combination with FLOT in the perioperative treatment of HER2-positive, localized esophagogastric adenocarcinoma—a phase II trial of the AIO study group (AIO STO 0321). Front Oncol 2023;13:1272175.)| false
• Search Google Scholar
• Export Citation

Goetze TO, Hofheinz RD, Schmalenberg H, et al. Perioperative ramucirumab in combination with FLOT versus FLOT alone for resectable esophagogastric adenocarcinoma (RAMSES/FLOT7) with high rate of signet cell component: final results of the multicenter, randomized phase II/III trial of the German AIO and Italian GOIM. J Clin Oncol 2022;40(Suppl 16):Abstract 4042.

• PubMed
Goetze TO, Hofheinz RD, Schmalenberg H, Perioperative ramucirumab in combination with FLOT versus FLOT alone for resectable esophagogastric adenocarcinoma (RAMSES/FLOT7) with high rate of signet cell component: final results of the multicenter, randomized phase II/III trial of the German AIO and Italian GOIM. J Clin Oncol 2022;40(Suppl 16):Abstract 4042.)| false
• Search Google Scholar
• Export Citation

Takahari D, Kawazoe A, Machida N, et al. Phase 2 study of trastuzumab deruxtecan in the neoadjuvant treatment for patients with HER2-positive gastric and gastroesophageal junction adenocarcinoma (EPOC2003). J Clin Oncol 2022;40(Suppl 16):Abstract TPS4161.

• PubMed
Takahari D, Kawazoe A, Machida N, Phase 2 study of trastuzumab deruxtecan in the neoadjuvant treatment for patients with HER2-positive gastric and gastroesophageal junction adenocarcinoma (EPOC2003). J Clin Oncol 2022;40(Suppl 16):Abstract TPS4161.)| false
• Search Google Scholar
• Export Citation